⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of XVIVO Perfusion AB and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
XVIVO Perfusion AB
↗Gothenburg, Sweden
XVIVO is a leading medical technology company dedicated to extending the life of all major organs—lungs, hearts, livers, and kidneys—to enable more transplantations and save more lives. Founded in 1998, the company develops innovative technologies and services for organ preservation, transport, and assessment, aiming to increase organ utilization and improve outcomes for transplant teams worldwide.
The company operates through segments including Thoracic, Abdominal, and Services. Its product portfolio includes the XVIVO Perfusion System (XPS), Kidney Assist Transport, and various perfusion solutions like STEEN Solution and Perfadex. XVIVO is headquartered in Mölndal/Gothenburg, Sweden, and is listed on Nasdaq Stockholm.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:-
Industry:Medical Devices
Sub-Industry:Organ Preservation & Transplantation
SIZE & FINANCIALS
Employees:51-200
Founded:1998
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ Stockholm
Ticker:XVIVO
Market Cap:$8.41B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Medical Devices, Perfusion Solutions
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Transplant centers and research institutions globally
COMPETITION
Position:Leader
Competitors:Paragonix Technologies, TransMedics, OrganOx Limited, Bridge to Life Limited, Waters Medical Systems
LEADERSHIP
Key Executives:
Christoffer Rosenblad - CEO
Kristoffer Nordström - CFO
Jaya Tiwari - SVP Global Medical Affairs
Board Members:Gosta Johannesson (CHM), Dag Andersson (PRE), Lars Henriksson, Lena Hoglund, Yvonne Martensson
LINKS
Website:xvivogroup.cpm
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with XVIVO Perfusion AB. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.